CX3CL1 and neoplasm: Remarkably, our findings from the tumour prophylactic vaccination experiments (Figure 2D) demonstrate that only lower doses (1 ng or 10 ng) of CX3CL1 exhibit an enhanced anti-tumour effect of ICD, whereas use of a high dose (100 ng) leads to almost complete absence of the anti-tumour effect (Figure 2D).